Charles River Laboratories International
Charles River Laboratories International Inc is an American contract research organization providing pre-clinical drug discovery and safety assessment services to the pharmaceutical industry. The company operates through three segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions, offering laboratory animal models, safety pharmacology, biologics testing, and endotoxin detection. Principal revenue streams derive from fee-for-service research contracts, animal model sales, testing kits, and clinical trial support agreements. Core end markets serve biopharmaceutical corporations, biotechnology startups, academic research institutions, and government health agencies globally. Charles River Laboratories holds the world-leading market share position in pre-clinical laboratory animal research models and safety testing services. The corporation is headquartered in Wilmington, Massachusetts, and its common stock trades on the New York Stock Exchange.
21 of the funds FundTelligence covers report a position in Charles River Laboratories International.
- Legal name
- CHARLES RIVER LABORATORIES INTERNATIONAL INC
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 21
Funds holding Charles River Laboratories International
- Nordea Global Small Cap — Nordea Funds · 2.07 % (full portfolio disclosed, September 2026)
- Nordea Global Small Cap Enhanced — Nordea Funds · 2.06 % (full portfolio disclosed, September 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 1.59 % (full portfolio disclosed, October 2026)
- Delphi Global — Storebrand · 1.23 % (full portfolio disclosed, October 2026)
- Templeton Global Smaller Companies Fund — Franklin Templeton · 1.11 % (full portfolio disclosed, September 2026)
- T. Rowe Price Global Focused Growth Equity Fund — T. Rowe Price · 0.96 % (full portfolio disclosed, September 2026)
- BNP US Small Cap — BNP Paribas · 0.65 % (full portfolio disclosed, June 2026)
- BNP Health Care Innovators — BNP Paribas · 0.65 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 21 funds holding it.